We exhibit our ongoing multicenter, prospective, single-arm, phase II trial of docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor (PEG-G-CSF) support for chemotherapy-naive elderly patients with advanced nonesmall-cell lung cancer (NSCLC) (University Hospital Medical Information Network database: UMIN000030598). Docetaxel monotherapy is the Japanese standard of care for chemotherapy-naive elderly patients with advanced NSCLC. Docetaxel plus ramucirumab showed superior survival benefit over docetaxel monotherapy in the second-line setting for NSCLC. A Japanese phase II study comparing docetaxel plus ramucirumab and docetaxel monotherapy in the second-line setting showed febrile neutropenia (FN) incidence of approximately one-third in the docetaxel plus ramucirumab arm. Docetaxel plus ramucirumab could be a promising candidate for elderly patients with NSCLC, but such high FN incidence is a clinically critical concern. To overcome this problem, we adopt a routine primary prophylactic PEG-G-CSF with docetaxel plus ramucirumab therapy. We hypothesize that primary prophylactic PEG-G-CSF reduces FN and maximizes the efficacy of docetaxel plus ramucirumab in Japanese elderly patients with NSCLC. Intravenous docetaxel (60 mg/m 2 , day 1) plus ramucirumab (10 mg/kg, day 1) with subcutaneous PEG-G-CSF (3.6 mg, day 2) every 3 weeks is administered until progression. The primary endpoint is overall response rate (ORR). We decided the threshold ORR to be 20%, and the expected ORR 35%. Taking statistical points (a/b errors: 0.05/0.80) and ineligible patients into account, the sample size was set at 65. When the study results are promising, we will conduct a phase III trial to compare docetaxel plus ramucirumab with PEG-G-CSF support versus docetaxel monotherapy for chemotherapy-naive elderly patients with NSCLC.
Introduction
As societies are aging worldwide, elderly patients with lung cancer, especially nonesmall-cell lung cancer (NSCLC), represent an increasing trend. Chemotherapy is the standard of care for patients with advanced and metastatic disease. Molecular-targeted therapies are generally recommended even for elderly patients with NSCLC harboring driver oncogene alterations such as epidermal growth factor mutation (EGFR) mutations, anaplastic lymphoma kinase (ALK ) fusions, c-ros oncogene 1 (ROS1)-fusions, and v-raf murine sarcoma viral oncogene homolog B1 (BRAF ) mutations. In those without such gene alterations, cytotoxic agents are still indicated. Cytotoxic monotherapies such as vinorelbine, gemcitabine, and docetaxel are standard regimens for elderly patients with NSCLC. [1] [2] [3] Recent studies have shown effectiveness of carboplatin-based platinum doublets, such as carboplatin plus weekly paclitaxel or nab-paclitaxel. 4, 5 In Japan, docetaxel monotherapy is the standard of care for chemotherapy-naive elderly patients with advanced NSCLC, according to the results of our phase III trial comparing docetaxel and vinorelbine monotherapies (WJTOG9904). 3 However, its therapeutic effect is not exemplary, and advancement of cytotoxic regimens has reached a plateau. Therefore, molecular-targeted therapies that are also effective in elderly patients are expected. Vascular endothelial growth factor (VEGF) inhibitor is one such candidate. Ramucirumab is a fully-human immunoglobulin G1 monoclonal antibody that binds with high affinity to VEGF receptor-2, preventing VEGF binding and activation. 6 In a pivotal phase III study (REVEL), docetaxel plus ramucirumab demonstrated superior overall response rate (ORR) and progression-free survival (PFS) over docetaxel monotherapy in second-line chemotherapy for advanced NSCLC. These differences in ORR and PFS were translated into overall survival (OS) benefit, and docetaxel plus ramucirumab showed superior OS over docetaxel monotherapy. 7 This evidence prompted us to investigate docetaxel plus ramucirumab for chemotherapy-naive elderly patients. However, in a similarly designed Japanese randomized phase II trial (JVCG), febrile neutropenia (FN) was observed in 34.2% of the docetaxel plus ramucirumab arm. 8 This high incidence of FN is a clinical concern when using docetaxel plus ramucirumab for elderly patients. Gandara et al showed that FN was more frequent in Japanese than in Western populations even when the same regimen was administered. 9 To overcome this problem, we adopt pegylated-granulocyte-colony stimulating factor (PEG-G-CSF) support. The American Society of Clinical Oncology (ASCO) practice guideline recommends primary prophylactic G-CSF when the risk of FN is approximately 20% or higher. 10 PEG-G-CSF demonstrated reduction of FN incidence administered only once a cycle in many types of cancers. 11 In patients with NSCLC, the incidence of FN could also be reduced by PEG-G-CSF. Based on the above background, we hypothesize that primary prophylactic PEG-G-CSF reduces FN and maximizes the efficacy of docetaxel plus ramucirumab in Japanese elderly patients with NSCLC.
Patients and Methods

Study Design and Objective
This is a prospective, multicenter, single-arm, phase II study conducted by West Japan Oncology Group (WJOG) (Figure 1 ). The primary endpoint is ORR. Secondary endpoints are PFS, OS, disease control rate, and safety. The registration period is set at 2 years from February 2018. Both follow-up and analysis periods were decided at 1 year. This study is conducted in compliance with the principles of the Declaration of Helsinki, and is registered in the University Hospital Medical Information Network database (UMIN000030598).
Eligibility Criteria
Key inclusion and exclusion criteria are shown in Table 1 .
Treatment Plan
Intravenous docetaxel (60 mg/m 2 , day 1) plus ramucirumab (10 mg/kg, day 1) with subcutaneous PEG-G-CSF (3.6 mg, day 2) every 3 weeks is administered until progression. Continuous docetaxel or ramucirumab monotherapy is permitted when intolerable toxicities occur, but clinical benefit is obtained by each drug.
Efficacy and Safety Evaluation
Computed tomography (CT) or magnetic resonance imaging scan of the brain, CT scans of the chest and abdomen, a bone scan or positron emission tomography scan, and an electrocardiogram are required before enrollment. Tumor assessments are carried out at baseline, every 6 weeks until 24 weeks from enrollment, and every 9 weeks thereafter. The tumor response will be evaluated in accordance 
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Docetaxel Plus Ramucirumab with PEG-G-CSF with the Response Evaluation Criteria in Solid Tumors, version 1.1. Adverse events will be evaluated using the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 4.0.
Statistical Analyses
We decided the threshold ORR to be 20%, and the expected ORR 35%. Based on this assumption, the number of patients needed to provide the 80% power for a 1-sided 0.05 level of type I error was calculated to be 59. Taking ineligible patients into account, the sample size was set at 65. PFS and OS will be analyzed using the Kaplan-Meier method to estimate the median points with 95% confidence interval.
Discussion
To the best of our knowledge, there is almost no evidence evaluating the effectiveness of primary prophylactic PEG-G-CSF support in advanced NSCLC. When the study results are promising, we will conduct a phase III trial to compare docetaxel plus ramucirumab with PEG-G-CSF support versus docetaxel monotherapy for chemotherapy-naive elderly patients with NSCLC.
Conclusion
Our study will be able to evaluate the efficacy and safety of docetaxel plus ramucirumab with primary prophylactic PEG-G-CSF support for chemotherapy-naive elderly patients with advanced NSCLC.
